文献速递类风湿关节炎

早期关节炎队列中优化甲氨蝶呤剂量与临床结局的关联

Optimal methotrexate dose is associated with better clinical outcomes than non-optimal dose in daily practice: results from the ESPOIR early arthritis cohort.
PubMed 文献 · Ann Rheum Dis · 2017-09-02

基于ESPOIR早期关节炎队列,评估以甲氨蝶呤(MTX)为首个DMARD的早期类风湿关节炎(RA)患者中,优化MTX剂量对2年症状和结构疗效的影响。结果显示仅26.4%患者达到优化剂量,优化剂量与1年ACR-EULAR缓解(OR 4.28,95%CI 1.86-9.86)和正常功能(OR 4.36,95%CI 2.03-9.39)显著相关,但对放射学进展无影响。

要点

  • 仅26.4%的早期RA患者接受了优化MTX剂量治疗。
  • 优化MTX剂量与1年ACR-EULAR缓解和正常功能显著相关。
  • 优化MTX剂量对2年放射学进展无显著影响。

核心结论

  • 在早期关节炎日常实践中,优化MTX剂量比非优化剂量更有效实现缓解和功能改善。
  • 优化MTX剂量对2年放射学进展无影响。

研究设计与样本

  • 研究基于ESPOIR早期关节炎队列,纳入符合ACR-EULAR RA标准且以MTX为首个DMARD的患者。
  • 优化MTX剂量定义为前3个月≥10 mg/周,6个月未达DAS28缓解时升级至≥20 mg/周或0.3 mg/kg/周。
  • 采用广义logistic回归调整相关变量评估疗效。

主要发现

  • 第一年随访中314例(53%)RA患者以MTX为首个DMARD,平均剂量12.2±3.8 mg/周。
  • 仅26.4%(n=76)患者达到优化MTX剂量。
  • 调整后,优化vs非优化MTX剂量1年ACR-EULAR缓解OR 4.28(95%CI 1.86-9.86)。
  • 优化vs非优化MTX剂量1年正常功能(HAQ≤0.5)OR 4.36(95%CI 2.03-9.39)。
  • 优化MTX剂量对放射学进展无影响,第二年结果类似。

关键数值与推荐

  • 优化MTX剂量定义:前3个月≥10 mg/周,6个月未达DAS28缓解时升级至≥20 mg/周或0.3 mg/kg/周。
  • 1年ACR-EULAR缓解OR 4.28(95%CI 1.86-9.86)。
  • 1年正常功能(HAQ≤0.5)OR 4.36(95%CI 2.03-9.39)。

临床怎么用

  • 在早期RA日常实践中,应尽早使用优化MTX剂量(前3个月≥10 mg/周,必要时6个月升级至≥20 mg/周或0.3 mg/kg/周)以改善缓解和功能。
  • 优化MTX剂量可能不延缓放射学进展,需结合其他治疗策略。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Although methotrexate (MTX) is the consensual first-line disease-modifying antirheumatic drug (DMARD) for rheumatoid arthritis (RA), substantial heterogeneity remains with its prescription and dosage, which are often not optimal. OBJECTIVE: To evaluate the symptomatic and structural impact of optimal MTX dose in patients with early RA in daily clinical practice over 2 years. METHODS: Patients included in the early arthritis ESPOIR cohort who fulfilled the ACR-EULAR (American College of Rheumatology/European League against Rheumatism) criteria for RA and received MTX as a first DMARD were assessed. Optimal MTX dose was defined as ≥10 mg/week during the first 3 months, with escalation to ≥20 mg/week or 0.3 mg/kg/week at 6 months without Disease Activity Score in 28 joints remission. Symptomatic and structural efficacy with and without optimal MTX dose was assessed by generalised logistic regression with adjustment for appropriate variables. RESULTS: Within the first year of follow-up, 314 patients (53%) with RA received MTX as a first DMARD (mean dose 12.2±3.8 mg/week). Only 26.4% (n=76) had optimal MTX dose. After adjustment, optimal versus non-optimal MTX dose was more efficient in achieving ACR-EULAR remission at 1 year (OR 4.28 (95% CI 1.86 to 9.86)) and normal functioning (Health Assessment Questionnaire ≤0.5; OR at 1 year 4.36 (95% CI 2.03 to 9.39)), with no effect on radiological progression. Results were similar during the second year. CONCLUSION: Optimal MTX dose is more efficacious than non-optimal dose for remission and function in early arthritis in daily practice, with no impact on radiological progression over 2 years.

来源:Ann Rheum Dis,查看原文。版权归原作者所有。

引用

  1. Gaujoux-Viala C, Rincheval N, Dougados M, et al. Optimal methotrexate dose is associated with better clinical outcomes than non-optimal dose in daily practice: results from the ESPOIR early arthritis cohort. Ann Rheum Dis. 2017. PMID: 28866645. doi:10.1136/annrheumdis-2017-211268

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。